INVENTIONS FOR LICENSE
MCL 187.0: Treatment of Mental Conditions Including Depression
Perry Renshaw, M.D., Ph.D.
- Treatment of Depression
- Treatment of Schizophrenia
- Treatment of Substance Abuse
Background and Description
The invention is based on the discovery that patients suffering from depression have decreased levels of adenosine in the brain. This leads to the hypothesis that disorders like depression, schizophrenia, etc. can be treated by agents that cause increased levels of adenosine in the brain.
Potential Commercial Uses
The invention comprises a method of treating disorders like depression, by administering a compound that can inhibit uptake of adenosine, which inhibits its breakdown in the brain, or which supplies or releases the compound. In addition to depression, the invention may be useful for treatment of bipolar disorder, manic depression, schizophrenia, or substance abuse.
Publication and Patent Status
McLean Hospital is the owner of U.S. Patent Number 6,258,794 claiming this invention. (USPTO # 6,258,794)
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax